Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma.

Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma.
复制标题

DOI:
10.1172/jci.insight.160513
复制
发表时间:
2022-07-08
期刊:
影响因子:
8
通讯作者:
DeCaprio, James A.
DeCaprio, James A.
中科院分区:
医学1区
文献类型:
--
作者:
Ananthapadmanabhan, Varsha;Frost, Thomas C.;Soroko, Kara M.;Knott, Aine;Magliozzi, Brianna J.;Gokhale, Prafulla C.;Tirunagaru, Vijaya G.;Doebele, Robert C.;DeCaprio, James A.

文献摘要

参考文献

被引文献

相似文献

默克尔细胞癌(MCC)是一种侵袭性皮肤神经内分泌癌,有两种病因。默克尔细胞多瘤病毒(MCPyV)整合存在于约80%的MCC中。病毒阳性MCC(MCCP)肿瘤几乎没有体细胞突变,通常表达WT p53(TP 53)。相比之下,病毒阴性MCC(MCCN)肿瘤呈现高肿瘤突变负荷和主要UV突变特征。MCCN肿瘤通常含有突变的TP 53。MCCP肿瘤表达2种病毒蛋白:MCPyV小T抗原和截短形式的大T抗原。MCPyV ST特异性激活MDM 2(p53的E3泛素连接酶)的表达,以抑制p53介导的肿瘤抑制。在这项研究中,我们评估了米拉美坦,一种有效的,选择性的,口服MDM 2抑制剂在几种MCC模型中的疗效。米拉美坦降低WT p53 MCC细胞系的细胞活力,并引发快速和持续的p53应答。在MKL-1异种移植物和患者来源的异种移植物模型中,米拉美坦显示出剂量依赖性的肿瘤生长抑制。在这里,沿着关于米拉美坦在WT p53 MCC肿瘤中的疗效的临床前数据,我们报告了几种可用于未来MCC研究的体外和体内模型。
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin with 2 etiologies. Merkel cell polyomavirus (MCPyV) integration is present in about 80% of all MCC. Virus-positive MCC (MCCP) tumors have few somatic mutations and usually express WT p53 (TP53). By contrast, virus-negative MCC (MCCN) tumors present with a high tumor mutational burden and predominantly UV mutational signature. MCCN tumors typically contain mutated TP53. MCCP tumors express 2 viral proteins: MCPyV small T antigen and a truncated form of large T antigen. MCPyV ST specifically activates expression of MDM2, an E3 ubiquitin ligase of p53, to inhibit p53-mediated tumor suppression. In this study, we assessed the efficacy of milademetan, a potent, selective, and orally available MDM2 inhibitor in several MCC models. Milademetan reduced cell viability of WT p53 MCC cell lines and triggered a rapid and sustained p53 response. Milademetan showed a dose-dependent inhibition of tumor growth in MKL-1 xenograft and patient-derived xenograft models. Here, along with preclinical data for the efficacy of milademetan in WT p53 MCC tumors, we report several in vitro and in vivo models useful for future MCC studies.
DOI: 10.1371/journal.ppat.1006020
发表时间: 2016-11
期刊: PLoS pathogens
影响因子: 6.7
作者:
Berrios C;Padi M;Keibler MA;Park DE;Molla V;Cheng J;Lee SM;Stephanopoulos G;Quackenbush J;DeCaprio JA
通讯作者: DeCaprio JA
DOI: 10.1093/nar/gkw523
发表时间: 2016-07-27
影响因子: 14.9
作者:
Fischer M;Grossmann P;Padi M;DeCaprio JA
通讯作者: DeCaprio JA
DOI: 10.1038/nature08822
发表时间: 2010-02-18
期刊: Nature
影响因子: 64.8
作者:
通讯作者: --
DOI: 10.1158/0008-5472.can-15-0702
发表时间: 2015-09-15
期刊: Cancer research
影响因子: 11.2
作者:
Harms PW;Vats P;Verhaegen ME;Robinson DR;Wu YM;Dhanasekaran SM;Palanisamy N;Siddiqui J;Cao X;Su F;Wang R;Xiao H;Kunju LP;Mehra R;Tomlins SA;Fullen DR;Bichakjian CK;Johnson TM;Dlugosz AA;Chinnaiyan AM
通讯作者: Chinnaiyan AM
DOI: 10.1038/onc.2016.502
发表时间: 2017-07-13
期刊: Oncogene
影响因子: 8
作者:
Fischer M
通讯作者: Fischer M